---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-091463"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-04-10T23:59:59+00:00"
generated_at: "2026-06-04T00:25:54.418309+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Interim Phase 2 data for AMX0035 shows clinically meaningful effects in Wolfram syndrome (n=8)

## Summary
- C-peptide AUC increased +15.6 ng*min/mL at Week 24; 7 of 8 participants had shorter time to peak C-peptide.
- HbA1c reduced by 0.26% on average; 6 of 8 improved; time in target glucose range improved by +7.1%.
- Visual acuity improved in 5 of 8 participants; one participant changed from legally blind to sighted.
- All 8 participants showed disease stability or improvement per CGIC and PGIC; no serious AEs related to AMX0035.

## SEC filing metadata
- accession: 0001193125-24-091463
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-04-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312524091463/0001193125-24-091463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312524091463/d818999d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-091463
- JSON: https://secwatch.observer/filing/0001193125-24-091463.json
- Plain text: https://secwatch.observer/filing/0001193125-24-091463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.